about
Cyclooxygenase-2: a therapeutic target in angiogenesis.Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.Involvement of PGE2 and the cAMP signalling pathway in the up-regulation of COX-2 and mPGES-1 expression in LPS-activated macrophages.Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.Inhibitory effects of sigma-2 receptor agonists on T lymphocyte activation.Cyclooxygenase-2 deficiency in macrophages leads to defective p110γ PI3K signaling and impairs cell adhesion and migration.Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receEffect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes.Thyroid hormone regulation of RC3, a brain-specific gene encoding a protein kinase-C substrate.Prostanoid function and cardiovascular diseaseCot/Tpl2 and PKCζ cooperate in the regulation of the transcriptional activity of NFATc2 through the phosphorylation of its amino-terminal domain☆Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cellsAn Essential Role of the Nuclear Factor of Activated T Cells in the Regulation of the Expression of the Cyclooxygenase-2 Gene in Human T Lymphocytes
P50
Q35077006-12A3B1D7-3135-40AE-B696-EE135E0A61A9Q37231752-E649420F-1FEA-4FF9-B73B-96D62F4226D5Q39407863-908E1952-B0A1-46A2-8F6D-86BCB26EA039Q39671951-89EF4B18-24EF-456D-8BAD-23CE169D8422Q40341163-ADD5C3C2-D8B3-4620-915F-FEBDCD184073Q41216280-795FFEAB-4195-4EFC-B2AB-40B9339FB788Q44430991-9A52E618-BC7B-4B58-9401-CABBA6C00AA8Q45003981-1A15A030-08DE-4AE2-AD5D-C7EB30499369Q45069278-0C4884BB-42EC-48DD-A36A-EB0108EC2B74Q48239094-6D4E3F21-551A-4498-954E-313D3759D010Q58869382-4F8C0B32-9424-4889-9E65-E7E7E94C3C6FQ58869388-E25361BE-67F9-4C0B-8007-17E9AB129281Q58869398-F4720C89-CC2B-4C0D-8FE3-C2A356211700Q58869426-90E7468A-901A-4A4A-9D8B-C629047AEBE8
P50
description
researcher
@en
wetenschapper
@nl
name
Iñiguez MA
@nl
Miguel Angel Iñiguez
@en
type
label
Iñiguez MA
@nl
Miguel Angel Iñiguez
@en
altLabel
Miguel Angel Iñiguez Peña
@en
prefLabel
Iñiguez MA
@nl
Miguel Angel Iñiguez
@en
P106
P31
P496
0000-0001-8262-6119